Text size Exelon stock offers a little bit of offense to go with its defense. Dreamstime The yield curve briefly inverted this past week—and that’s a recession signal that is either like Paul Revere’s...
Tag: AbbVie
AbbVie stock is up 20% YTD: is it out of juice now?
AbbVie Inc (NYSE: ABBV) is already up about 20% for the year but Boston Private’s Shannon Saccocia continues to see more upside in 2022. AbbVie is a great way to play the healthcare space Saccoc...
Invest in AbbVie? I’ve Made My Decision
Kind of like that bunny that keeps on going… pharmaceutical firm AbbVie (ABBV) , long a Sarge fave, and now one of the oldest continuous long positions on my book, keeps on going… higher. ...
Humana, Cisco, Waste Connections, Stanley Black & Decker, AbbVie
Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.7875 per share payable on April 29, 2022 to stockholders of record as of the close of business on ...
AbbVie tops fourth-quarter estimates by 3%
AbbVie (NYSE: ABBV) reports $3.31 EPS in the fourth quarter, which tops the $3.28 analyst estimate by $0.03. However, the company recorded $14.89 billion in revenue in the same quarter, a little less ...
AbbVie Stock: Fourth Quarter Comes In Mixed, But Earnings Guidance Beats
AbbVie stock ticked down early Wednesday after the pharmaceutical company reported adjusted earnings of $3.31 per share on $14.89 billion in fourth-quarter sales. X On average, analysts polled by Fact...
Pharmaron Beijing Says Profit Rose Amid U.S., UK Expansion
Pharmaron Beijing’s shares trade in Hong Kong and Shenzhen. Photographer: Roy Liu/Bloomberg © 2020 Bloomberg Finance LP Pharmaron Beijing, a China-based pharmaceutical research services company ...
Biotech Stocks Are Due to Bounce Back. This One Stands Out.
Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...